Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Clinical and molecular characteristics of bloodstream infections caused by Candida albicans in children from 2003 to 2011 M.-H. Tsai, S.-H. Wang, J.-F.

Impact of infection on admission and of the process of care on mortality of patients admitted to the Intensive Care Unit: the INFAUCI study J. Gonçalves-Pereira,

Thirty-day mortality of nosocomial systemic bacterial infections according to antibiotic susceptibility in an 800-bed teaching hospital in France D.

Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome J. Guinea, M. Torres-Narbona, P.

Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel R. Ben-Ami, G. Rahav, H. Elinav,

Incidence and outcome of Staphylococcus aureus endocarditis—a 10-year single-centre northern European experience H. Asgeirsson, A. Thalme, M. Kristjansson,

D. Khalil, M. Hultin, M.U. Rashid, B. Lund

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Migrant health—a cause for concern?

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Candida glabrata fungaemia in intensive care units

Whole genome analysis of Mycobacterium tuberculosis isolates from recurrent episodes of tuberculosis, Finland, 1995–2013 V. Korhonen, P.W. Smit, M. Haanperä,

A. F. Simonetti, C. Garcia-Vidal, D. Viasus, D. García-Somoza, J

A.E. Muller, U. Theuretzbacher, J.W. Mouton

Distribution of fluconazole-resistant Candida bloodstream isolates among hospitals and inpatient services in Israel R. Ben-Ami, G. Rahav, H. Elinav,

J. Rello, E. Afonso, T. Lisboa, M. Ricart, B. Balsera, A. Rovira, J

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

Potential risk factors for infection with Candida spp

D. Rodriguez, B. J. Park, B. Almirante, M. Cuenca-Estrella, A. M

Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp. H. Wisplinghoff, H. Seifert,

Trends in length of stay, mortality and readmission among patients with community- acquired bacteraemia M. Søgaard, R.W. Thomsen, R.B. Bang, H.C. Schønheyder,

Clinical Microbiology and Infection

Impact of infection on admission and of the process of care on mortality of patients admitted to the Intensive Care Unit: the INFAUCI study J. Gonçalves-Pereira,

Temporal trends in Enterobacter species bloodstream infection: a population-based study from 1998–2007 M.N. Al-Hasan, B.D. Lahr, J.E. Eckel-Passow, L.M.

Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit.

Vector control: a cornerstone in the malaria elimination campaign

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients

A. Solé, P. Morant, M. Salavert, J. Pemán, P. Morales

Sofie Arens, Jan Verhaegen, Ludo Verbist

G. Höffken Clinical Microbiology and Infection

Evaluation of the effect of appropriate antimicrobial therapy on mortality associated with Acinetobacter nosocomialis bacteraemia S.-C. Kuo, Y.-T. Lee,

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman Clinical.

Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae.

Corticosteroids for the treatment of human infection with influenza virus: a systematic review and meta-analysis J.-W. Yang, L.-C. Fan, X.-Y. Miao, B.

M.N. Al-Hasan, B.D. Lahr, J.E. Eckel-Passow, L.M. Baddour

J. Bodilsen, C. T. Brandt, A. Sharew, M. Dalager-Pedersen, T

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

B. Sádaba, J.R. Azanza, M.A. Campanero, E. García-Quetglas

Previously unknown species of Aspergillus

Long-term mortality following bloodstream infection

Update on antifungal resistance in Aspergillus and Candida

Impact of Candida spp. isolation in the respiratory tract in patients with intensive care unit-acquired pneumonia S. Terraneo, M. Ferrer, I. Martín-Loeches,

R. Luzzati, B. Allegranzi, L. Antozzi, L. Masala, E. Pegoraro, A

Eleven-year retrospective survey of candidaemia in a university hospital in southwestern Greece A. Spiliopoulou, S. Vamvakopoulou, C. Bartzavali, G.

M. Bassetti, M.P. Molinari, M. Mussap, C. Viscoli, E. Righi

Testing patients with non-specific symptoms for antibodies against Borrelia burgdorferi sensu lato does not provide useful clinical information about.

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia M.-S. Hsu,

Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective.

Statin use and clinical outcomes among pneumonia patients

Changing pattern of candidaemia 2001–2006 and use of antifungal therapy at the University Hospital of Vienna, Austria E. Presterl, F. Daxböck, W. Graninger,

Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

Predictors of clinical and microbiological treatment failure in patients with methicillin- resistant Staphylococcus aureus (MRSA) bacteraemia: a retrospective.

Survival of rhinoviruses on human fingers

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre R.R. Laffer, P. Graber, P.E. Ochsner, W. Zimmerli

Virology: a scientific discipline facing new challenges

Modelling during an emergency: the 2009 H1N1 influenza pandemic

R. Khatib, G. Simeunovic, M. Sharma, M. G. Fakih, L. B. Johnson, L

In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species† C.B. Moore,

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

CMI readers' survey Clinical Microbiology and Infection

Rajko Saletinger, Mario Poljak, Franc Strle

The future of diagnostic bacteriology

Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection A. Russo, M. Falcone, M. Fantoni, R. Murri,

Presentation transcript:

Differential association of fluconazole dose and dose/MIC ratio with mortality in patients with Candida albicans and non-albicans bloodstream infection T. Brosh-Nissimov, R. Ben-Ami Clinical Microbiology and Infection Volume 21, Issue 11, Pages 1011-1017 (November 2015) DOI: 10.1016/j.cmi.2015.07.005 Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Survival rate as a function of fluconazole dose/MIC ratio. (a, b) Survival rates for a range of fluconazole dose/MIC ratios: (a) Candida albicans bloodstream infection; (b) non-albicans Candida bloodstream infection. (c) Number of Candida isolates by species in each fluconazole dose/MIC range. Clinical Microbiology and Infection 2015 21, 1011-1017DOI: (10.1016/j.cmi.2015.07.005) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 Association of fluconazole pharmacodynamic parameters with early treatment outcome. Interaction between (a) fluconazole dose, (b) dose/MIC ratio and (c) 24-h area under the concentration–time curve (AUC24)/MIC ratio and early response to treatment, defined as clearance of Candida from blood and survival to day 7 from the onset of candidaemia. NAC, non-albicans Candida. Clinical Microbiology and Infection 2015 21, 1011-1017DOI: (10.1016/j.cmi.2015.07.005) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 3 Multivariate analysis of risk factors for 30-day mortality. Hazard ratios (circles) and 95% CIs (whiskers) are shown for variables assessed for their effects on 30-day mortality. (a) All episodes of candidaemia. (b) Candida albicans bloodstream infection. (C) Non-albicans Candida bloodstream infection. AUC24, 24-h area under the concentration–time curve; SOFA, Sequential Organ Failure Assessment. Clinical Microbiology and Infection 2015 21, 1011-1017DOI: (10.1016/j.cmi.2015.07.005) Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions